Where Pharmaceuticals
Meet Medical Devices.
Angiotech Pharmaceuticals designs drug-eluting technologies, biomaterials, and targeted delivery systems that reduce complications from implants, surgery, and acute injury — improving outcomes across cardiovascular medicine, interventional oncology, ophthalmology, and wound closure.
Combining Pharmaceuticals with Devices That Heal
Four therapeutic platforms — one integrated approach to reducing device-related complications through pharmaceutical innovation.
Drug-Eluting Devices
Paclitaxel-coated stents and balloons that reduce restenosis and tissue overgrowth after intervention.
- Paclitaxel coatings
- Restenosis reduction
- Coronary & peripheral
Wound Closure
Advanced sutures, meshes, and hemostatic devices engineered for stronger healing and fewer complications.
- Antimicrobial sutures
- Surgical meshes
- Hemostatic agents
Ocular Therapeutics
Targeted drug delivery for anterior and posterior segment disease, including sustained-release implants.
- Sustained release
- Intraocular implants
- Glaucoma & AMD
Implant Coatings
Proprietary biomaterials and polymer platforms that improve biocompatibility of implanted medical devices.
- Polymer platforms
- Anti-fibrotic coatings
- Custom formulation
Why Partners Choose Us
We built the playbook for integrating pharmaceuticals with medical devices — and we keep refining it, one platform at a time.
Drug-Device Integration
First-in-class expertise combining pharmaceuticals directly with implantable devices — not siloed R&D.
Proprietary Biomaterials
Two decades developing polymer platforms and coatings that deliver drugs where and when the body needs them.
Clinically Validated
Our paclitaxel-coating technology helped define the modern drug-eluting stent category.
Cross-Disciplinary Science
Chemists, materials engineers, and clinicians collaborate under one roof to accelerate translation.
Physician-Led Development
Programs are co-developed with interventional cardiologists, surgeons, and ophthalmologists.
Industry Legacy
A foundational innovator whose work continues to influence combination-product regulation and design.
One Platform. Four Therapeutic Areas.
Angiotech's research spans interventional oncology, wound closure, ophthalmology, and the biomaterials used in modern medical implants.
Key Milestones
From founding vision to defining an industry category — the moments that shaped Angiotech's role in modern combination-product medicine.
Company Founded
Angiotech Pharmaceuticals is founded in Vancouver with a vision of combining pharmaceuticals with medical devices.
Paclitaxel Coating Program
Launched the paclitaxel-eluting technology program that would go on to define a new category of cardiovascular devices.
First Drug-Eluting Stent
Our paclitaxel-coating technology helped enable the first commercially approved drug-eluting coronary stents.
Portfolio Expansion
Expanded into wound closure, interventional oncology, and ophthalmology — extending combination-product expertise into new areas.
Biomaterials Platform
Consolidated proprietary polymer and biomaterials platforms into a shared R&D backbone for device partners.
Industry Recognition
Recognized as a foundational innovator in combination-product design, influencing FDA and international frameworks.
Next-Gen Delivery
Advanced next-generation targeted drug delivery systems for ophthalmology and interventional oncology.
The Combination Future
Continuing to push the intersection of pharmaceuticals, biomaterials, and devices to improve patient outcomes worldwide.
Trusted by Clinicians & Partners
What our research collaborators, clinical partners, and licensees say about working with Angiotech.
"Angiotech's paclitaxel-coating chemistry set the reference point for a generation of drug-eluting devices. Their work reshaped interventional cardiology."
Dr. Elena Ruiz
Interventional Cardiologist
"Partnering on a combination product with Angiotech, we moved from bench formulation to clinical prototype in under a year — their biomaterials team is world-class."
Dr. James Chen
R&D Director, Device OEM
"Their integrated approach — chemistry, materials, and clinical insight under one roof — is what makes real combination products possible."
Dr. Sarah Johnson
Principal Investigator
Combination Products as Infrastructure
Angiotech Pharmaceuticals is a Canadian specialty medical device and pharmaceutical company focused on technologies for implantable devices, surgery, and targeted drug delivery. We became widely known for pioneering the combination of pharmaceuticals with medical devices — particularly through drug-coated stent technology.
Our research emphasizes reducing complications associated with implants, surgical procedures, and acute injuries by integrating pharmaceuticals with innovative device designs across interventional oncology, wound closure, ophthalmology, and biomaterials.
Patient-Centered Science
1M+Every platform starts with a clinical problem — reducing complications for the patient receiving the implant.
Combination-Product Leadership
150+We helped establish the drug-eluting device category and continue to advance the standard of care.
Collaborative R&D
4We partner with device OEMs, academic centers, and clinicians to bring combination products to market.
Ready to Build the Next Combination Product?
Talk to our team about partnering on your next implant, delivery system, or biomaterial platform.